Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.16T -25.1%
Revenue (ttm)	1.64T +9.9%
Net Income	195.47B +160.3%
EPS	16,988.64 +160.3%
Shares Out	11.51M
PE Ratio	5.92
Forward PE	6.64
Dividend	600.00 (0.60%)
Ex-Dividend Date	Dec 29, 2025

Volume	19,965
Open	98,400
Previous Close	99,100
Day's Range	98,400 - 101,700
52-Week Range	98,400 - 199,400
Beta	0.00
Analysts	Buy
Price Target	201,000.00 (+99.8%)
Est. Earnings	Nov 13, 2026

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,893
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2025, Daewoong Pharmaceutical's revenue was 1.57 trillion, an increase of 10.42% compared to the previous year's 1.42 trillion. Earnings were 195.86 billion, an increase of 691.83%.

Analyst Summary

According to 10 analysts, the average rating for 069620 stock is "Buy." The 12-month stock price target is ₩201,000, which is an increase of 99.80% from the latest price.

Price Target

₩201,000

(99.80% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error